Latest News & Features

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine Search
Americas
The US Court of Appeals for the Federal Circuit has reversed a $482 million jury decision against Johnson & Johnson subsidiary Cordis, ruling that its Cypher stent did not infringe a patent held by radiologist Bruce Saffran.   8 April 2013
India's Novartis ruling: the implications for patent owners
Asia
India’s Supreme Court has rejected pharmaceutical company Novartis’s application to patent an updated version of its leukaemia drug Glivec, agreeing with the Comptroller General that it lacked novelty.   3 April 2013
Asia
India’s patent office has published final guidelines for examining biotechnology patents, after accepting comments on a draft version published in December.   2 April 2013
Americas
On March 16, 2013, the ‘first inventor to file’ provisions of the AIA came into effect. MaryAnne Armstrong looks at the implications.   1 April 2013
Americas
Challenging the validity of a patent through the court systems of Europe and the US can be a time-consuming and expensive process. Jane Wainwright and Daniel Young look at the alternatives.   1 April 2013
Americas
Biocomparable medicines are currently among the hottest topics in regard to life sciences legislation in Mexico. Daniel Sánchez and Victor Ramirez investigate.   1 April 2013
Asia
Therapeutic substances used under the folk medicine practices of what is known as ‘traditional knowledge’ are protected by special provisions under Indian patent law. Archana Shanker and Vidisha Garg explore the pros and cons.   1 April 2013
Europe
While changes to European law seem to allow fairly broad exemptions to the patent law for companies developing generic alternatives to branded drugs, the reality is different, as Rafał Witek explains.   1 April 2013
Asia
New definitions of efficacy are helping to clarify pharmaceutical patent challenges under the notorious Section 3d of the Indian Patents Act, says Rahul Vartak.   1 April 2013
Biotechnology
In its effort to tackle the threat of ‘evergreening’, the CJEU has caused some uncertainty about supplementary protection certificates, as Jaap Mannaerts explains.   1 April 2013